Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center and Non-interventional Registry of BrentuximabVedotinin Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma or Classical Hodgkin Lymphoma

NCT03766516 is registered in ClinicalTrials.gov with Samsung Medical Center as lead sponsor.

NCT NCT03766516
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03766516 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center and Non-interventional Registry of BrentuximabVedotinin Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma or Classical Hodgkin Lymphoma
Lead sponsor
Samsung Medical Center
Phase
Observational
Overall status
Completed
Start date
November 1, 2018
Completion date
December 30, 2021
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory anaplastic large cell lymphoma & hodgkin lymphoma